Hantz Financial Services, Inc. Ascendis Pharma A/S Transaction History
Hantz Financial Services, Inc.
- $5.69 Billion
- Q1 2025
A detailed history of Hantz Financial Services, Inc. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 90 shares of ASND stock, worth $14,154. This represents 0.0% of its overall portfolio holdings.
Number of Shares
90Holding current value
$14,154% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ASND
# of Institutions
270Shares Held
61.9MCall Options Held
151KPut Options Held
226K-
Ra Capital Management, L.P. Boston, MA10.3MShares$1.62 Billion33.28% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$862 Million4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.22MShares$821 Million13.16% of portfolio
-
Janus Henderson Group PLC London, X04.49MShares$706 Million0.4% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$669 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $8.78B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...